NCT04383509 (ECT-CCT) is a NA clinical trial of Cognitive Control Training in Depressive Episode, sponsored by University Ghent.

Who is sponsoring NCT04383509?

NCT04383509 is sponsored by University Ghent.

What drugs are being tested in NCT04383509?

Interventions in NCT04383509: Cognitive Control Training, Active Control.

What condition does NCT04383509 study?

NCT04383509 studies Depressive Episode, Electroconvulsive Therapy, Cognitive Remediation.

Is NCT04383509 still recruiting?

NCT04383509 is currently terminated. Last updated 30 November 2023.

Last reviewed 2023-11-30 · How we verify

NCT04383509: ECT-CCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electroconvulsive Treatment Followed by Cognitive Control Training

Terminated NA Last updated 30 November 2023

What this trial tests

NA trial testing Cognitive Control Training in Depressive Episode in 21 participants. Terminated before completion.

Timeline

10 May 2020

Primary endpoint
14 June 2023

1 July 2023

Quick facts

Lead sponsor	University Ghent
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	21
Start date	10 May 2020
Primary completion	14 June 2023
Estimated completion	1 July 2023
Sites	1 location across Belgium

Drugs / interventions tested

Cognitive Control Training
Active Control — full drug profile →

Conditions studied

Depressive Episode — all drugs for Depressive Episode →
Electroconvulsive Therapy — all drugs for Electroconvulsive Therapy →
Cognitive Remediation — all drugs for Cognitive Remediation →

Sponsor

University Ghent

Who can join

Adults 18 to 70, any sex, with Depressive Episode or Electroconvulsive Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high. Cognitive side effects of ECT, such as reduced cognitive control, might trigger mechanisms that increase relapse in patients. As such, cognitive control training (CCT) holds promise as a non-pharmacological strategy to improve long-term effects of ECT (i.e., increase remission, and reduce depression relapse).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cognitive remediation following electroconvulsive therapy in patients with treatment resistant depression: randomized controlled trail of an intervention for relapse prevention - study protocol.
Van de Velde N, Kappen M, Koster EHW, Hoorelbeke K, et al · · 2020 · cited 3× · PMID 32938410 · DOI 10.1186/s12888-020-02856-x
Systematic review on relapse-prevention strategies following successful electroconvulsive therapy for major depressive disorder.
Rovers JJE, van Zeijl NT, Tendolkar I, Dols A, et al · · 2026 · PMID 41530963 · DOI 10.1192/bjo.2025.10946

Verify or expand the search:

Other trials of Cognitive Control Training

Trials testing the same drug.

NCT04779437 — Bayesian Sequential Single Case Methods to Personalize Low-Intensity Psychological Interventions: Initial Pilot Work · NA · completed
NCT05683028 — RCT for Electroconvulsive Treatment Followed by Cognitive Control Training · NA · completed
NCT03684031 — Impact of Cognitive Control Training on Anger Symptoms and Reactive Aggression · NA · completed
NCT03527550 — Cognitive Control Training for Urgency in a Naturalistic Clinical Setting · NA · terminated
NCT02880215 — Development of Attention Bias Modification for Depression · NA · completed

Other recruiting trials for Depressive Episode

Currently open trials in the same condition.

NCT06426134 — Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS · NA · recruiting
NCT06152705 — Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression · NA · recruiting
NCT05678907 — Predictive Value of the DD4 Questionnaire on Depressive Relapse After Hospitalization · recruiting
NCT05641623 — OSU6162 as add-on in SSRI/SNRI-resistant Depression · Phase 2 · recruiting
NCT02481245 — BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study · Phase 2 · recruiting

Other University Ghent trials

Trials by the same sponsor.

NCT07398053 — General Practitioner & Pharmacist Support for Discontinuing Long-term Antidepressants in Clinically Stable Patients · NA · not yet recruiting
NCT07343258 — Pilot Study on Follow-Up of (Acutely) Suicidal Individuals From the Flemish Suicide Helpline · NA · recruiting
NCT07091071 — Evaluation of the CochSyn Device in Clinical Practice · NA · completed
NCT07259408 — Co-creation of Tools for People in Detention With Suicidal Thoughts and/or Behavior · recruiting
NCT07176156 — Evaluation of the Quality of Chat Conversations With the Suicide Helpline Zelfmoordlijn 1813 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04383509 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Ghent
Last refreshed: 30 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04383509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing